BioDelivery Announces Completion of Trial; Catalyst Could Invigorate Share Price

Wed, 07/27/2011 - 07:17 EDT - Seeking Alpha

By VFC: Earlier this year, BioDelivery Sciences (BDSI) announced the completion of enrollment for its ongoing Phase III trial for BEMA Buprenorphine in the treatment of chronic pain, and the next logical step would be the completion of the trial itself.That news hit the wires on Monday morning.According to the press release, results from the trial should be released in mid-to-late September of this year, which would put the company on track to file a New Drug Application (NDA) for BEMA Bup in the first half of 2012.The chronic pain market is a multi-billion dollar industry, and some projections have BEMA Bup reaching up to half a billion in sales annually, making the current market cap of this company look pretty weak for those that believe the lofty expectations can be achieved.With REMS delays paralyzing the potential of ONSOLIS - BDSI's first product to market utilizing the BEMAComplete Story »

Original article
Login or register to post comments

BioDelivery Sciences: Early Results Reinforce Long Term Potential
By VFC: BioDelivery Sciences (BDSI) has started making some noise again after a year of a relative flatline as discussions with the FDA were taking place to finalize the REMS issues regarding Onsolis in the United States.
BioDelivery Sciences: A Case Of Two Steps Forward, One Step Back?
By VFC: BioDelivery Sciences (BDSI) shares about tripled earlier this year when the company signed a worldwide licensing and development agreement with Endo Pharmaceuticals (
Endo Pharma Deal Validates BioDelivery Sciences Pipeline Potential
By Mike Havrilla:BioDelivery Sciences (BDSI) is a specialty pharmaceutical company that is focused on the development of opiate dependence and pain drugs which represent novel formulations of marketed drugs utilizing the Company's BioErodible MucoAdhesive or BEMA Film Technology that allows for the rapid absorption and delivery of drugs into the bloodstream from the inside of the mouth.
BioDelivery On Track For Mid-Year NDA Filing
By Len Zehr:BioDelivery Sciences (NASDAQ:BDSI) is on track to file a new drug application with the FDA this summer for its Bunavail treatment for opioid dependence, one of two Phase 3 candidates in its product pipeline.
BioDelivery Sciences International: The Pieces Are Coming Together
Smith On Stocks submits: BioDelivery Sciences International (BDSI) is making steady progress in advancing its pipeline and also has the stage set for a pickup in Onsolis sales.
Time to Add BioDelivery Shares After Good Drug Trial News and Multiple Products in Pipeline
VFC submits: An early morning press release from BioDelivery Sciences (BDSI) announced that the ongoing BEMA Buprenorphine Phase III trial is more than 50% enrolled and is expected to be completed on schedule.
BDSI Might Again Be Ready For Prime Time
By VFC: With nearly five million shares traded and a 120% price increase on Friday, BioDelivery Sciences (BDSI) was unsurprisingly one of the most talked about stocks heading into the weekend after the small company whose stock has a daily trading average of under 300,00
BioDelivery Sciences International: Strong Upside Potential
By Scott Matusow:In this article, I will be featuring an interesting little bio-pharma that a few investors brought to my attention over the past few weeks. This one might be a long term buy and hold, albeit risky for the long term, as most of these lower priced bio-pharmas certainly are. I believe the risk/reward ratio at the company's current price level is favorable for at least a mid-term swing trade.
Canadian Launch Of Onsolis Has BioDelivery On The Radar
By VFC: Good news for investors of BioDelivery Sciences (BDSI). A Monday morning press release announced that the company's treatment for breakthrough pain in cancer patients, Onsolis, will be available for sale on the Canadian market at some point during the current quarter. Onsolis
BioDelivery Sciences International: Why I Believe Patience Will Reward Investors
VFC submits: BioDelivery Sciences International (BDSI) and marketing partner Meda AB announced earlier this week that Onsolis, a treatment for pain in cancer patients which utilizes BioDelivery's BEMA drug delivery technology, has received regulatory approval in Canada.Onsolis will be will be marketed in Canada by Meda Valeant Pharma Canada Inc.

Main menu

Secondary menu

BioDelivery Announces Completion of Trial; Catalyst Could Invigorate Share Price

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu